Sana Biotechnology Inc vs NEOS S&P 500 High Income ETF — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while NEOS S&P 500 High Income ETF trades at $53.44. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | SPYI | |
|---|---|---|
Market Cap | $873.84M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $5.92 | $54.07 |
52-Week Low | $2.68 | $47.98 |
Enterprise Value | $848.03M | — |
Trailing returns across standard periods
Latest headlines on both assets
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →